After FDA rejection, Regeneron gains nod in Europe for T-cell engager odronextamab

Five months after the FDA rejected Regeneron’s bid for accelerated approval of its T-cell engager odronextamab because of the immaturity of its confirmatory trial, the European Union has signed off on the treatment for two types of blood cancers.